101 related articles for article (PubMed ID: 29200214)
1. [Skin toxicity of monoclonal antibodies].
Cignola S; Campagna S; Gonella S
Assist Inferm Ric; 2017; 36(4):214-221. PubMed ID: 29200214
[No Abstract] [Full Text] [Related]
2. Prognostic Significance of Cutaneous Adverse Events Associated With Pembrolizumab Therapy.
Lo JA; Fisher DE; Flaherty KT
JAMA Oncol; 2015 Dec; 1(9):1340-1. PubMed ID: 26270186
[No Abstract] [Full Text] [Related]
3. [Differential papulosquamous skin manifestations diagnosis].
Kienast AK
Kinderkrankenschwester; 2009 Dec; 28(12):501-8. PubMed ID: 20063655
[No Abstract] [Full Text] [Related]
4. Drug-induced livedo and the EGFR pathway.
de Saint Martin L; Pasquier E
Eur J Dermatol; 2008; 18(5):601-3. PubMed ID: 18779114
[No Abstract] [Full Text] [Related]
5. Spironolactone-associated cutaneous effects: a case report and a review of the literature.
Gupta AK; Knowles SR; Shear NH
Dermatology; 1994; 189(4):402-5. PubMed ID: 7873830
[TBL] [Abstract][Full Text] [Related]
6. [Generalized pruritic eruption during terbinafine treatment].
Amouri M; El Euch D; El Ouni B; Daoued O; Ouselati MH; Ferjani M; Dhahri AB
Presse Med; 2008 Dec; 37(12):1836-40. PubMed ID: 18656325
[No Abstract] [Full Text] [Related]
7. Paronychia induced by the epidermal growth factor receptor inhibitor cetuximab.
Lee SL; Tan BS; Chan LC
J Oncol Pharm Pract; 2013 Sep; 19(3):273-8. PubMed ID: 23161875
[TBL] [Abstract][Full Text] [Related]
8. Acquired perforating dermatosis associated with natalizumab.
Piqué-Duran E; Eguía P; García-Vázquez O
J Am Acad Dermatol; 2013 Jun; 68(6):e185-7. PubMed ID: 23680214
[No Abstract] [Full Text] [Related]
9. Injection site reaction to adalimumab: Positive skin test and successful rapid desensitisation.
Bavbek S; Ataman Ş; Bankova L; Castells M
Allergol Immunopathol (Madr); 2013; 41(3):204-6. PubMed ID: 23063342
[No Abstract] [Full Text] [Related]
10. Adverse Reactions to Biologics: Melanoma (Ipilimumab, Nivolumab, Pembrolizumab).
Hwang SJE; Fernández-Peñas P
Curr Probl Dermatol; 2018; 53():82-92. PubMed ID: 29131040
[TBL] [Abstract][Full Text] [Related]
11. Acute generalized exanthematous pustulosis due to etodolac in a patient with an iliopsoas muscle abscess.
Nakamura Y; Takemoto A; Muto M
Acta Derm Venereol; 2011 Sep; 91(5):589-90. PubMed ID: 21629972
[No Abstract] [Full Text] [Related]
12. Nineteen cases of persistent pruritic nodules and contact allergy to aluminium after injection of commonly used aluminium-adsorbed vaccines.
Bergfors E; Björkelund C; Trollfors B
Eur J Pediatr; 2005 Nov; 164(11):691-7. PubMed ID: 16044278
[TBL] [Abstract][Full Text] [Related]
13. Management of 'in-field' skin toxicity in head and neck cancer patients treated with combined cetuximab and radiotherapy.
Cante D; La Porta MR; Franco P; Sciacero P; Girelli GF; Marra A; Numico G; Denaro N; Russi EG; Ricardi U
Oncology; 2013; 85(5):257-61. PubMed ID: 24192693
[TBL] [Abstract][Full Text] [Related]
14. Clomipramine-induced hypersensitivity syndrome with unusual clinical features.
Nishimura Y; Kitoh A; Yoshida Y; Tanaka T
J Am Acad Dermatol; 2005 Nov; 53(5 Suppl 1):S231-3. PubMed ID: 16227097
[TBL] [Abstract][Full Text] [Related]
15. Clinical management of cutaneous toxicity of anti-EGFR agents.
Monti M; Motta S
Int J Biol Markers; 2007; 22(1 Suppl 4):S53-61. PubMed ID: 17520582
[TBL] [Abstract][Full Text] [Related]
16. Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer.
Ocvirk J; Cencelj S
J Eur Acad Dermatol Venereol; 2010 Apr; 24(4):453-9. PubMed ID: 19793151
[TBL] [Abstract][Full Text] [Related]
17. Microbiological analysis of epidermal growth factor receptor inhibitor therapy-associated paronychia.
Eames T; Grabein B; Kroth J; Wollenberg A
J Eur Acad Dermatol Venereol; 2010 Aug; 24(8):958-60. PubMed ID: 20015177
[TBL] [Abstract][Full Text] [Related]
18. Carotenoderma in association with trastuzumab treatment.
Lee YB; Lee KJ; Cho E; Cho BK; Park HJ
J Am Acad Dermatol; 2012 Nov; 67(5):e201-2. PubMed ID: 23062912
[No Abstract] [Full Text] [Related]
19. Recurrent erythema annulare centrifugum during ustekinumab treatment in a psoriatic patient.
Chou WT; Tsai TF
Acta Derm Venereol; 2013 Mar; 93(2):208-9. PubMed ID: 22983014
[No Abstract] [Full Text] [Related]
20. Cutaneous lesions in the rat following administration of an irreversible inhibitor of erbB receptors, including the epidermal growth factor receptor.
Brown AP; Dunstan RW; Courtney CL; Criswell KA; Graziano MJ
Toxicol Pathol; 2008 Apr; 36(3):410-9. PubMed ID: 18467688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
